HRS-3095 / Jiangsu Hengrui Pharma - LARVOL DELTA

HRS-3095-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria